Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerdulatinib in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT04021082Phase 3Withdrawn
- Sponsor
- Portola Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of cerdulatinib in peripheral T-cell lymphoma (PTCL), sponsored by Portola Pharmaceuticals. Planned start Nov 2019; status: withdrawn.
02
Drugs
cerdulatinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04021082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04021082.